Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancer.

Histology Lymph nodes Lymphatic metastasis Non-small cell lung cancer Pathologic N1

Journal

Acta chirurgica Belgica
ISSN: 0001-5458
Titre abrégé: Acta Chir Belg
Pays: England
ID NLM: 0370571

Informations de publication

Date de publication:
25 Feb 2024
Historique:
medline: 26 2 2024
pubmed: 26 2 2024
entrez: 26 2 2024
Statut: aheadofprint

Résumé

Previous studies investigating whether metastatic lymph node count is a relevant prognostic factor in pathological N1 non-small cell lung cancer (NSCLC), showed conflicting results. Hypothesizing that outcome may also be related to histological features, we determined the prognostic impact of single versus multiple metastatic lymph nodes in different histological subtypes for patients with stage II-N1 NSCLC. We performed a retrospective cohort study using data from the Netherlands Cancer Registry, including patients treated with a surgical resection for stage II-N1 NSCLC (TNM 7 After complete resection of histologically proven stage II-N1 NSCLC, 1309 patients were analysed, comprising 871 patients with pN1a and 438 with pN1b. The median number of pathologically examined nodes (N1 + N2) was 9 (interquartile range 6-13). 5-year OS was 53% for pN1a versus 51% for pN1b. In multivariable analysis, OS was significantly different between pN1a and pN1b (HR 1.19, 95% CI 1.01-1.40). When stratifying for histology, the prognostic impact of pN1a/b was only observed in adenocarcinoma patients (HR 1.44, 95% CI 1.15-1.81). Among patients with stage II-N1 adenocarcinoma, the presence of multiple metastatic nodes had a significant impact on survival, which was not observed for other histological subtypes. If further refinement as to lymph node count will be considered for incorporation into a new staging system, evaluation of the role of histology is recommended.

Sections du résumé

BACKGROUND UNASSIGNED
Previous studies investigating whether metastatic lymph node count is a relevant prognostic factor in pathological N1 non-small cell lung cancer (NSCLC), showed conflicting results. Hypothesizing that outcome may also be related to histological features, we determined the prognostic impact of single versus multiple metastatic lymph nodes in different histological subtypes for patients with stage II-N1 NSCLC.
METHODS UNASSIGNED
We performed a retrospective cohort study using data from the Netherlands Cancer Registry, including patients treated with a surgical resection for stage II-N1 NSCLC (TNM 7
RESULTS UNASSIGNED
After complete resection of histologically proven stage II-N1 NSCLC, 1309 patients were analysed, comprising 871 patients with pN1a and 438 with pN1b. The median number of pathologically examined nodes (N1 + N2) was 9 (interquartile range 6-13). 5-year OS was 53% for pN1a versus 51% for pN1b. In multivariable analysis, OS was significantly different between pN1a and pN1b (HR 1.19, 95% CI 1.01-1.40). When stratifying for histology, the prognostic impact of pN1a/b was only observed in adenocarcinoma patients (HR 1.44, 95% CI 1.15-1.81).
CONCLUSION UNASSIGNED
Among patients with stage II-N1 adenocarcinoma, the presence of multiple metastatic nodes had a significant impact on survival, which was not observed for other histological subtypes. If further refinement as to lymph node count will be considered for incorporation into a new staging system, evaluation of the role of histology is recommended.

Identifiants

pubmed: 38404182
doi: 10.1080/00015458.2024.2322243
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-12

Auteurs

Julianne Ruiter (J)

Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
Department of Pulmonary Diseases, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.

Adrianus de Langen (A)

Department of Thoracic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Kim Monkhorst (K)

Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Alexander Veenhof (A)

Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Houke Klomp (H)

Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Jasper Smit (J)

Department of Thoracic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Egbert Smit (E)

Department of Pulmonary Diseases, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
Department of Thoracic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Ronald Damhuis (R)

Department of Research, Netherlands Comprehensive Cancer Organization, Godebaldkwartier 419, 3511 DT Utrecht, The Netherlands.

Koen Hartemink (K)

Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital. Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Classifications MeSH